US Bancorp DE Grows Position in Moderna, Inc. (NASDAQ:MRNA)

US Bancorp DE grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 13.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,962 shares of the company’s stock after buying an additional 1,981 shares during the quarter. US Bancorp DE’s holdings in Moderna were worth $705,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Wilmington Savings Fund Society FSB grew its stake in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna during the fourth quarter valued at about $37,000. Venturi Wealth Management LLC raised its holdings in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares in the last quarter. Finally, Blue Trust Inc. lifted its stake in Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after purchasing an additional 388 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Stock Performance

MRNA opened at $35.96 on Tuesday. Moderna, Inc. has a twelve month low of $29.25 and a twelve month high of $170.47. The firm’s fifty day moving average is $36.53 and its two-hundred day moving average is $48.45. The firm has a market cap of $13.87 billion, a PE ratio of -3.88 and a beta of 1.86.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on MRNA shares. Morgan Stanley cut their price target on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. Royal Bank of Canada reissued a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. JPMorgan Chase & Co. set a $45.00 price objective on Moderna in a research report on Friday, February 14th. Evercore ISI set a $50.00 price target on Moderna in a report on Friday, February 14th. Finally, The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $60.63.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.